Details for New Drug Application (NDA): 085825
NDA 085825 describes TRIAMCINOLONE ACETONIDE, which is a drug marketed by Actavis Mid Atlantic, Alkem Labs Ltd, Alpharma Us Pharms, Ambix, Chartwell Rx, Cosette Pharms Nc, Encube, Fougera Pharms, Glenmark Pharms Ltd, Macleods Pharms, Micro Labs, Morton Grove, Padagis Us, Pharmaderm, Pharmafair, Pharmobedient, Strides Pharma, Sun Pharma Canada, Taro, Topiderm, Alembic, Amneal, Caplin, Dr Reddys, Eugia Pharma, Hikma, Long Grove Pharms, Mylan Labs Ltd, Parnell, Sandoz, Teva Pharms Usa, Watson Labs, Beach Prods, Epic Pharma Llc, Quagen, Aurobindo Pharma Ltd, Extrovis, Glenmark Speclt, Padagis Israel, Pharmazone, Rising, Sciegen Pharms, Apotex, and Perrigo Pharma Intl, and is included in ninety-eight NDAs. It is available from seventy suppliers. Additional details are available on the TRIAMCINOLONE ACETONIDE profile page.
The generic ingredient in TRIAMCINOLONE ACETONIDE is triamcinolone acetonide. There is one drug master file entry for this compound. Eighty suppliers are listed for this compound. Additional details are available on the triamcinolone acetonide profile page.
The generic ingredient in TRIAMCINOLONE ACETONIDE is triamcinolone acetonide. There is one drug master file entry for this compound. Eighty suppliers are listed for this compound. Additional details are available on the triamcinolone acetonide profile page.
Summary for 085825
| Tradename: | TRIAMCINOLONE ACETONIDE |
| Applicant: | Watson Labs |
| Ingredient: | triamcinolone acetonide |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 085825
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INJECTION | Strength | 40MG/ML | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
